153 related articles for article (PubMed ID: 21926398)
21. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study.
Bendell JC; Bekaii-Saab TS; Cohn AL; Hurwitz HI; Kozloff M; Tezcan H; Roach N; Mun Y; Fish S; Flick ED; Dalal D; Grothey A
Oncologist; 2012; 17(12):1486-95. PubMed ID: 23015662
[TBL] [Abstract][Full Text] [Related]
22. MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer.
Parikh AR; Lee FC; Yau L; Koh H; Knost J; Mitchell EP; Bosanac I; Choong N; Scappaticci F; Mancao C; Lenz HJ
Clin Cancer Res; 2019 May; 25(10):2988-2995. PubMed ID: 30224341
[TBL] [Abstract][Full Text] [Related]
23. The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens.
Artac M; Bozcuk H; Pehlivan S; Akcan S; Pehlivan M; Sever T; Ozdogan M; Savas B
J Cancer Res Clin Oncol; 2010 Jun; 136(6):803-9. PubMed ID: 19908066
[TBL] [Abstract][Full Text] [Related]
24. Bevacizumab with FOLFIRI or XELIRI in the First-line Therapy of Metastatic Colorectal Carcinoma: Results from Czech Observational Registry.
Kocakova I; Melichar B; Kocak I; Bortlicek Z; Büchler T; Dusek L; Petruzelka L; Kohoutek M; Prausová J; Finek J; Mohelnikova-Duchonova B; Vyzula R
Anticancer Res; 2015 Jun; 35(6):3455-61. PubMed ID: 26026110
[TBL] [Abstract][Full Text] [Related]
25. Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab.
Malka D; Boige V; Jacques N; Vimond N; Adenis A; Boucher E; Pierga JY; Conroy T; Chauffert B; François E; Guichard P; Galais MP; Cvitkovic F; Ducreux M; Farace F
Ann Oncol; 2012 Apr; 23(4):919-27. PubMed ID: 21825101
[TBL] [Abstract][Full Text] [Related]
26. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
Bennouna J; Borg C; Delord JP; Husseini F; Trillet-Lenoir V; Faroux R; François E; Ychou M; Goldwasser F; Bouché O; Senellart H; Kraemer S; Douillard JY
Clin Colorectal Cancer; 2012 Mar; 11(1):38-44. PubMed ID: 21803002
[TBL] [Abstract][Full Text] [Related]
27. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
Tabernero J; Van Cutsem E; Lakomý R; Prausová J; Ruff P; van Hazel GA; Moiseyenko VM; Ferry DR; McKendrick JJ; Soussan-Lazard K; Chevalier S; Allegra CJ
Eur J Cancer; 2014 Jan; 50(2):320-31. PubMed ID: 24140268
[TBL] [Abstract][Full Text] [Related]
28. Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer.
Volz NB; Stintzing S; Zhang W; Yang D; Ning Y; Wakatsuki T; El-Khoueiry RE; Li JE; Kardosh A; Loupakis F; Cremolini C; Falcone A; Scherer SJ; Lenz HJ
Pharmacogenomics J; 2015 Feb; 15(1):69-76. PubMed ID: 25069475
[TBL] [Abstract][Full Text] [Related]
29. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
[TBL] [Abstract][Full Text] [Related]
30. Treatment of metastatic colorectal cancer with or without bevacizumab: can the neutrophil/lymphocyte ratio predict the efficiency of bevacizumab?
Dirican A; Varol U; Kucukzeybek Y; Alacacioglu A; Erten C; Somali I; Can A; Demir L; Bayoglu IV; Akyol M; Yildiz Y; Koyuncu B; Coban E; Tarhan MO
Asian Pac J Cancer Prev; 2014; 15(12):4781-6. PubMed ID: 24998541
[TBL] [Abstract][Full Text] [Related]
31. FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study.
Iwamoto S; Takahashi T; Tamagawa H; Nakamura M; Munemoto Y; Kato T; Hata T; Denda T; Morita Y; Inukai M; Kunieda K; Nagata N; Kurachi K; Ina K; Ooshiro M; Shimoyama T; Baba H; Oba K; Sakamoto J; Mishima H
Ann Oncol; 2015 Jul; 26(7):1427-33. PubMed ID: 25908603
[TBL] [Abstract][Full Text] [Related]
32. Germline polymorphisms in genes maintaining the replication fork predict the efficacy of oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
Arai H; Xiao Y; Millstein J; Wang J; Battaglin F; Kawanishi N; Jayachandran P; Soni S; Zhang W; Mancao C; Salhia B; Mumenthaler SM; Parikh AR; Lenz HJ
Br J Cancer; 2022 Jan; 126(1):72-78. PubMed ID: 34689170
[TBL] [Abstract][Full Text] [Related]
33. A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second-Line Treatment of Metastatic
Hecht JR; Benson AB; Vyushkov D; Yang Y; Bendell J; Verma U
Oncologist; 2017 Mar; 22(3):243-e23. PubMed ID: 28246207
[TBL] [Abstract][Full Text] [Related]
34. Randomized phase II trial of TEGAFIRI (tegafur/uracil, oral leucovorin, irinotecan) compared with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) in patients with unresectable/recurrent colorectal cancer.
Shigeta K; Hasegawa H; Okabayashi K; Tsuruta M; Ishii Y; Endo T; Ochiai H; Kondo T; Kitagawa Y
Int J Cancer; 2016 Aug; 139(4):946-54. PubMed ID: 27061810
[TBL] [Abstract][Full Text] [Related]
35. XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.
Uygun K; Bilici A; Kaya S; Oven Ustaalioglu BB; Yildiz R; Temiz S; Seker M; Aksu G; Cabuk D; Gumus M
Asian Pac J Cancer Prev; 2013; 14(4):2283-8. PubMed ID: 23725128
[TBL] [Abstract][Full Text] [Related]
36. Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels.
Kim S; Dobi E; Jary M; Monnien F; Curtit E; Nguyen T; Lakkis Z; Heyd B; Fratte S; Cléau D; Lamfichekh N; Nerich V; Guiu B; Demarchi M; Borg C
BMC Cancer; 2013 Dec; 13():611. PubMed ID: 24373251
[TBL] [Abstract][Full Text] [Related]
37. Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.
Kang BW; Kim TW; Lee JL; Ryu MH; Chang HM; Yu CS; Kim JC; Kim JH; Kang YK; Lee JS
Med Oncol; 2009; 26(1):32-7. PubMed ID: 18498064
[TBL] [Abstract][Full Text] [Related]
38. Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT).
Bennouna J; Phelip JM; André T; Asselain B; Sébastien Koné ; Ducreux M
Clin Colorectal Cancer; 2017 Jun; 16(2):129-140.e4. PubMed ID: 28277294
[TBL] [Abstract][Full Text] [Related]
39. Discontinuation of bevacizumab and FOLFIRI administered up to a maximum of 12 cycles as first-line therapy for metastatic colorectal cancer: a retrospective Italian study.
Rosati G; Cordio S; Aprile G; Butera A; Avallone A; Di Lucca G; De Pauli F; Parra HS; Reggiardo G; Bordonaro R
Invest New Drugs; 2012 Oct; 30(5):1978-83. PubMed ID: 21769636
[TBL] [Abstract][Full Text] [Related]
40. Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study).
Moriwaki T; Bando H; Takashima A; Yamazaki K; Esaki T; Yamashita K; Fukunaga M; Miyake Y; Katsumata K; Kato S; Satoh T; Ozeki M; Baba E; Yoshida S; Boku N; Hyodo I
Med Oncol; 2012 Dec; 29(4):2842-8. PubMed ID: 22209842
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
